Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Inclusion Criteria:

- Subjects must have a histologically or cytologically confirmed advanced solid tumor at
screening.

- Male or female equal or greater than 18 years of age.

- All female subjects of childbearing potential must each have a negative serum
pregnancy test result before initiating study treatment.

- An Eastern Cooperative Oncology Group (ECOG) performance status equal or less than 2

- Adequate bone marrow, liver, and renal function, defined as:

- Platelet count equal or greater than 75 x 10(9)/L

- Hemoglobin (Hb) equal or greater than 9.0 g/dL

- Absolute neutrophil count (ANC) equal or greater than 1.5 x 10(9)/L

- Total bilirubin equal or less than 1.5 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal or less
than 3 x ULN (equal or less than 5 x ULN for subjects with liver metastases)

- Serum creatinine equal or less than 1.5 x ULN

Exclusion Criteria:

- History of cardiac disease: Active coronary artery disease (CAD), defined as
myocardial infarction (MI), unstable angina, coronary bypass graft (CABG), or stenting
within 6 months prior to study entry (an MI that occurred > 6 months prior to study
entry is permitted)

- Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as equal or
greater than Grade 2 according to NCI CTCAE, version 4.0, or uncontrolled hypertension

- Active, clinically serious infection(s) defined as equal or greater than Grade 2
according to NCI CTCAE, version 4.0.

- Known metastatic brain or meningeal tumors, unless the subject is > 3 months from
definitive therapy and clinically stable (supportive therapy with steroids or
anticonvulsant medications is allowed) with respect to the tumor at the time of first
dose of study drug.

- Prior therapy with mesenchymal-epithelial transition factor (c-MET) inhibitors,
including ARQ 197.